Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Antares Pharma's peak revenue was $184.0M in 2021. The peak quarterly revenue was $48.7M in 2021(q4).
Antares Pharma's revenue increased from $4.0m in 2002 to $184.0M currently. That's a 4,504.43% change in annual revenue.
| Fiscal year / year | Antares Pharma revenue |
|---|---|
| 2009 | $8.3M |
| 2010 | $12.8M |
| 2011 | $16.5M |
| 2012 | $22.6M |
| 2013 | $20.6M |
| 2014 | $26.5M |
| 2015 | $45.7M |
| 2016 | $52.2M |
| 2017 | $54.5M |
| 2018 | $63.6M |
| 2019 | $123.9M |
| 2020 | $149.6M |
| 2021 | $184.0M |
Rate Antares Pharma's financial transparency
Antares Pharma saw the greatest revenue growth in 2006, when revenue increased by 191,760.06%.
Antares Pharma had the lowest revenue growth in 2015, when revenue changed by -99.83%.
| Year | Antares Pharma growth |
|---|---|
| 2009 | 47%↑ |
| 2010 | 54%↑ |
| 2011 | 28%↑ |
| 2012 | 37%↑ |
| 2013 | -9%↓ |
| 2014 | 29%↑ |
| 2015 | 72%↑ |
| 2016 | 14%↑ |
| 2017 | 4%↑ |
| 2018 | 17%↑ |
| 2019 | 95%↑ |
| 2020 | 21%↑ |
| 2021 | 23%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2010 | - | - | $3.1M | $3.3M |
| 2011 | $3.6M | $3.5M | $3.9M | $5.4M |
| 2012 | $6.9M | $4.5M | $5.7M | $5.5M |
| 2013 | $4.5M | $5.8M | $5.5M | $4.7M |
| 2014 | $5.2M | $6.3M | $6.6M | $8.4M |
| 2015 | $8.3M | $14.4M | $11.1M | $11.8M |
| 2016 | $12.3M | $12.2M | $13.5M | $14.2M |
| 2017 | $12.0M | $13.4M | $15.1M | $14.0M |
| 2018 | $12.7M | $14.2M | $17.9M | $18.8M |
| 2019 | $23.3M | $28.4M | $34.3M | $37.8M |
| 2020 | $33.1M | $32.4M | $40.0M | $44.1M |
| 2021 | $42.1M | $45.0M | $48.2M | $48.7M |
| 2022 | $41.6M | - | - | - |
Do you work at Antares Pharma?
Is Antares Pharma transparent about its revenue structure?
| CEO | Robert F. Apple |
| Company Type | Public |
| Employees Number | 165 |
| Date Founded | 1979 |
| Headquarters | Ewing, New Jersey |
| Number of Locations | 2 |
| Revenue | $184.0M |
| Net Income | $46,289,000 |
| Gross Proft | $115.7M (2021) |
| PE Ratio | 12.28 |
| Tax Rate | 0.3% |
| Market Capitalization | $568.3M |
| Total Assets | $257,505,000 |
| Ticker | ATRS |
Antares Pharma received early financing of $10.0M on 2007-02-28.
| Series | Round size | Date |
|---|---|---|
| Debt Financing | $10M | 02/2007 |
| Post Ipo Debt | $35M | 06/2017 |
| Investors | Security type |
|---|---|
| MMV FINANCIAL INC. | Debt Financing |
| HSBC Venture Capital Coverage Group | Debt Financing |
| HERCULES CAPITAL INC | Post Ipo Debt |
Zippia gives an in-depth look into the details of Antares Pharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Antares Pharma. The employee data is based on information from people who have self-reported their past or current employments at Antares Pharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Antares Pharma. The data presented on this page does not represent the view of Antares Pharma and its employees or that of Zippia.
Antares Pharma may also be known as or be related to ANTARES PHARMA INC., Antares Pharma, Antares Pharma Inc, Antares Pharma Inc. and Antares Pharma, Inc.